1. A Phase IIb, randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Issue 8 (4th March 2013) Authors: Ferrannini, E.; Seman, L.; Seewaldt‐Becker, E.; Hantel, S.; Pinnetti, S.; Woerle, H. J. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 8(2013:Aug.) Page Start: 721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia. Issue 12 (22nd August 2013) Authors: Rosenstock, J.; Seman, L. J.; Jelaska, A.; Hantel, S.; Pinnetti, S.; Hach, T.; Woerle, H. J. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 12(2013:Dec.) Page Start: 1154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Lack of drug–drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Issue 4 (22nd November 2012) Authors: Macha, S.; Rose, P.; Mattheus, M.; Pinnetti, S.; Woerle, H. J. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 4(2013:Apr.) Page Start: 316 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. Issue 3 (19th August 2013) Authors: Macha, S.; Mattheus, M.; Halabi, A.; Pinnetti, S.; Woerle, H. J.; Broedl, U. C. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 3(2014:Mar.) Page Start: 215 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. Issue 2 (19th August 2013) Authors: Macha, S.; Rose, P.; Mattheus, M.; Cinca, R.; Pinnetti, S.; Broedl, U. C.; Woerle, H. J. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 2(2014:Feb.) Page Start: 118 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Issue 7 (17th February 2013) Authors: Heise, T.; Seewaldt‐Becker, E.; Macha, S.; Hantel, S.; Pinnetti, S.; Seman, L.; Woerle, H. J. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 7(2013:Jul.) Page Start: 613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗